Sign In
21 MAR, 2012 - CaridianBCT Biotechnologies Research Highlights Published by DoD
3/21/2012

Mirasol Pathogen Reduction Technology System has Potential to Improve Blood Transfusions in the Field

 

LAKEWOOD, Colo.—March 21, 2012 —CaridianBCT, soon to be known as Terumo BCT, recently had research highlights published by the Department of Defense (DoD) Congressionally Directed Medical Research Program that discuss the potential for the Mirasol Pathogen Reduction System for Whole Blood to improve the safety of blood transfusions provided to military personnel in the field of combat.

 

Key Facts:

 

  • CaridianBCT's research aims to develop a portable device and disposable for pathogen reduction in fresh whole blood, which will minimize the risk of infectious disease transmission as well as potential adverse immunological effects of bypassing leukoreduction.
  • CaridianBCT's prototype for the device, the Mirasol System for Whole Blood, uses riboflavin (vitamin B2) and ultraviolet light to reduce the infectious pathogen load and inactivate leukocytes in whole blood. Validation and optimization studies are being conducted for the device's effectiveness against pathogens including bacteria, viruses and parasites. When completed, the Mirasol system will undergo operational testing in simulated combat environments.
  • CaridianBCT was awarded a DoD grant in 2008 for Medical Research Program Advanced Technology/Therapeutic Development to develop a pathogen reduction technology for whole blood that can reduce the risk of infectious disease transmission and unwanted transfusion reactions.
  • The Mirasol System for Whole Blood prototype, which is not approved by the U.S. Food and Drug Administration (FDA), is based on the Mirasol® Pathogen Reduction Technology System, which is approved for use in areas outside the United States.

 

Key Quotes:

 

Raymond Goodrich, Ph.D., Terumo BCT, Vice President of Scientific and Clinical Affairs

 

  • "The funds provided by this grant have allowed us to develop a transportable blood treatment system that can be used for the processing of whole blood in austere environments."
  • "This extends the capability to reduce infectious pathogen load and inactivate white blood cells to all three components of blood (red cells, platelets and plasma proteins) with one process, thus permitting the potential use of this product in combat field hospitals and far forward settings."

 

Key Resources:

 

Mirasol Pathogen Reduction Technology System

A Transportable Pathogen Reduction System for Treatment of Whole Blood

 

ABOUT TERUMO BCT:

 

CaridianBCT and Terumo Transfusion are becoming Terumo BCT, the world leader in blood component technology. Together, we believe in the potential of blood to do even more for the world than it does today. This belief unites our organization, inspires our innovation and strengthens our collaboration with customers to ultimately benefit the patients we all serve. The transition to Terumo BCT will be complete in April 2012.

 

Contact:                                                                                             

Laura Fusco

Global Corporate Communications

Phone: +1.303.205.2546

press@caridianbct.com